Perhaps I may comment first.
One of the additional unfortunate aspects of ALS is that there is little to no drug intervention therapy. There is one drug, Riluzole, that has efficacy with some patients. It needs to be used early in the diagnosis. It may delay symptoms for a brief period of time. Beyond that particular drug, there are no others. With ALS we encounter the dilemma that the pharmaceutical companies have of whether it's good business to be endeavouring to identify a molecule that will work for what is in the overall scheme of things something of an orphan disease. Consequently, there aren't many people who are going to take it. From a good corporate citizen point of view, it's the right thing to do. From a business perspective, they are challenged.